



# Global Market Analysis of World Congress on Diabetes and Metabolism

Yvonne Paul


Professor, Department of Science, Tshwane University of Technology, South Africa

## Scope and importance:

Diabetes is one of the most emerging diseases, which is becoming very common nowadays. Patients with high blood sugar will experience polyuria (frequent urination), meeting thirsty (polydipsia) and hungry (polyphagia). With the change in life style; our endocrine system of the body is getting disturbed. In order to get innovative, the Diabetes Metabolism Conference will focus on the latest and exciting innovations in all areas of diabetes and metabolism based research offering a unique opportunity for international explorers to assemble, network, talk and grasp new scientific innovations and ideas to prevent diabetes related ailments. To allocate advance researches, developments, druggists, scientists, technology challenges and improvement and alternative therapies, this meeting forms an excellent learning. The diabetes market, consisting mainly of Type 1 and Type 2 diabetes, is large and growing significantly. The global market value for diabetes therapies and diagnostics has reached to \$48.5 billion. The largest segment of the market, insulin products, is worth \$20.8 billion in the recent times, including administration and diagnostic devices. Monitoring devices and other related equipment, the second-largest market is established with an investment of \$13.5 billion in which was proposed for \$11.3. The fastest-growing segment of oral diabetic complication of hypoglycemia drugs manufacturing funding is \$14.13 in present scenario of diabetes market.


### Business and Economics of Diabetes:

Diabetes has become a lifestyle-related disease as it afflicts young and old. As the proportion of patients are growing rapidly across the globe, there has never been a stronger and more urgent need for novel therapeutic measures in clinical and preclinical evaluation, that arrest the growth of the disease. The diabetes market, consisting of mainly Type 1 and Type 2 diabetes, is large and growing significantly. The global market value for diabetes therapies and diagnostics has aroused to \$48.5 billion. The largest segment of the market, insulin products, is worth \$20.8 billion in recent days, including administration and diagnostic devices. Diabetes monitoring devices and other related equipment, the second-largest market is established with an investment of \$13.5 billion which was proposed for \$11.3. The fastest-growing segment of oral diabetic problems of hypoglycemia drugs manufacturing funding is \$14.13 in present time scenario of the diabetes market. Transparency Market Reports (TMR), who completed the research, found that the market was estimated to be worth US\$43.1 billion in 2016. It is projected to reach US\$58.4 billion by 2025. Type 2 diabetes is reported as being more prevalent and therapies to treat Type 2 have the highest gross on the market, above Type 1. The World Health Organization (WHO) reports that 422 million people



times the number of patients with diabetes in 1980. North America is expected to be the dominant market for diabetes

ugs due to unhealthy nutritional habits in patients. The re



### Market Analysis of Diabetes in Graphs

drugs due to unhealthy nutritional habits in patients. The research and development for diabetes drugs is also reported to grow due to higher incidence rates. The report suggests that competition will increase also as rival drug manufacturers contend for market domination. Some of the key players include Boehringer Ingelheim, Novo Nordisk and Bayer AG.

### Diabetes in America:

Diabetes remains the 7th leading cause of death in the United States in 2015, with 79,535 death certificates listing it as the underlying cause of death, and a total of 252,806 death certificates listing diabetes as an underlying or contributing cause of death.

- In 2015, 30.3 million Americans, or 9.4% of the population, had diabetes. Approximately 1.25 million American children and adults have type-1 diabetes.

- North America is the largest consumption place, with a consumption market share nearly 31.2% in 2017.

### Diabetes in Asia:

The prevalence of diabetes is increasing worldwide, particularly in Asia. The Diabetes Atlas published in 2013 reported that 366 million of individuals are affected by diabetes, and 36% of those affected live in the Western Pacific region, with a significant proportion in East Asia.

- The Asia-Pacific market for diabetes drugs is estimated to value USD 23.8 billion in 2019, and the market is expected to grow at the CAGR of 4.82%, during the forecast period.

### **Diabetes in Middle East and Africa:**

According to the International Diabetes Federation Atlas, 19.3 percent of adults aged 20 to 79 in the United Arab Emirates are diabetic. In Bahrain, the percentage rises to 19.6—and the statistic jumps to 20 percent for Kuwait, Qatar, and Saudi Arabia. According to the IDF Diabetes Atlas 8th Edition, approximately 38.7 million adults aged 20-79 years were living with diabetes in the Middle East and North Africa Region in 2017. Over two-thirds (67.3%) of adults with diabetes live in urban areas.

- In Middle East & Africa (MEA), 15.51 million people are suffering from diabetes, and this population is expected to increase in the forecast period with a CAGR of 4.46%.

- The Middle East & Africa diabetes drugs market (henceforth, referred to as the market studied) was valued at USD 2793.99 million in 2018, and it is expected to witness a CAGR of 6.48% during the forecast period 2019 - 2024, primarily due to the growing geriatric population.

### **Diabetes in Europe:**

There are about 60 million people with diabetes in the European Region, or about 10.3% of men and 9.6% of women aged 25 years and over. Prevalence of diabetes is increasing among all ages in the European Region, mostly due to increases in overweight and obesity, unhealthy diet and physical inactivity.

- The European diabetes devices market is expected to record a high CAGR of 7.51% during the forecast period (2019 - 2024), due to the growing prevalence of diabetes, growing geriatric population levels, unhealthy diet, and increasing levels of physical inactivity.

### **Rising Prevalence of Diabetes:**

- The market size, in 2017, for the global diabetes drugs market was registered to be USD 67.5 billion, and the market is expected to record a CAGR of 5.65% during the forecast period, 2019-2024.

- As per a WHO report, the global prevalence of diabetes among adults of over 18 years had accelerated from about 4.7%, in 1980, to over 8.5%, in 2014.

- Diabetes prevalence has been rising rapidly in the middle- and low-income countries. In 2015, about 1.6 million deaths were directly associated with diabetes, which was around 2.2 million in 2012.

- Almost half of all deaths attributable to high blood glucose occur before the age of 70 years. WHO projects that diabetes is likely to be the seventh leading cause of death by 2030.